Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wellbeing Digital Sciences Inc (OP: KONEF )

N/A UNCHANGED
Last Price Updated: 3:57 PM EST, Mar 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wellbeing Digital Sciences Inc

< Previous 1 2 3 Next >
World's Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees
The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gathered over 12,000 people from the entire psy 
Via Benzinga
Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Announces Cease Trade Order
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Provides Bi-Weekly Default Status Report
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial 
Via Benzinga
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion
From Wellbeing Digital Sciences Inc.
Via Business Wire
Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License
A Contract Research Organization (CRO) and a wholly-owned subsidiary of Wellbeing Digital Sciences Inc. 
Via Benzinga
Wellbeing Digital to Participate in The Global Biomedical Design Conference
From Wellbeing Digital Sciences Inc.
Via Business Wire
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established... 
Via Benzinga
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout
From WELLBEING DIGITAL SCIENCES
Via Business Wire
Wellbeing Provides Bi-Weekly Default Status Report
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event
From Wellbeing Digital Sciences Inc.
Via Business Wire
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
Wellbeing Provides Bi-Weekly Default Status Report
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.
From Wellbeing Digital Sciences Inc.
Via Business Wire
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a... 
Via Benzinga
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Announces Delay in Filing Its Financial Statements and Management Cease Trade Order
From Wellbeing Digital Sciences Inc.
Via Business Wire
Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers
In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council. 
Via Benzinga
Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Digital Announces Change of Auditor
From Wellbeing Digital Sciences Inc.
Via Business Wire
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a... 
Via Benzinga
Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
From Wellbeing Digital Sciences Inc.
Via Business Wire
Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada
From Wellbeing Digital Sciences Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.